Cancer Radiotherapie最新文献

{"title":"Radiotherapy of sinonasal cancers: 2025 update","authors":"Audrey Larnaudie ,&nbsp;Florent Carsuzaa ,&nbsp;Nolwenn Delaby ,&nbsp;Valérie Costes-Martineau ,&nbsp;Mélanie Doré ,&nbsp;Charles Dupin ,&nbsp;France Nguyen ,&nbsp;Pierre Blanchard ,&nbsp;Yoann Pointreau ,&nbsp;Ludovic de Gabory ,&nbsp;Juliette Thariat","doi":"10.1016/j.canrad.2025.104728","DOIUrl":"10.1016/j.canrad.2025.104728","url":null,"abstract":"<div><div>Sinonasal cancers, including tumours of the nasal cavity, ethmoid, maxillary, sphenoid, and frontal sinuses, account for 3 to 5 % of head and neck malignancies. While the majority are carcinomas, other histologic types such as mucosal melanomas, sarcomas, and lymphomas may also occur. These tumours often present with non-specific symptoms and exhibit a heterogeneous prognosis. The Réseau d’expertise français des cancers ORL rares (the French expert network for rare head and neck cancers), accredited by the Institut national du cancer (the French national cancer institute), is responsible for maintaining the national registry and coordinating rare cancer multidisciplinary tumour boards at both regional and national levels. These boards incorporate expert pathological review through Refcorpath (when appropriate) and provide therapeutic recommendations. Due to the distinct characteristics of these tumours, including histologic subtype, grade, risk of nodal involvement, and surgical approach, careful consideration must be given to target volume delineation during locoregional radiotherapy. This article provides an updated overview of the Société française de radiothérapie oncologique (the French society for radiation oncology) recommendations concerning the indications for radiotherapy in sinonasal cancers. It covers key aspects such as treatment planning, techniques, dose and volume specifications, and post-treatment follow-up.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104728"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy for laryngeal cancers: 2025 update","authors":"Audrey Maury ,&nbsp;Mathieu Bosset ,&nbsp;Alexandre Coutte ,&nbsp;Michel Lapeyre ,&nbsp;Nolwenn Delaby ,&nbsp;Pierre Blanchard ,&nbsp;Yoann Pointreau ,&nbsp;Julian Biau","doi":"10.1016/j.canrad.2025.104727","DOIUrl":"10.1016/j.canrad.2025.104727","url":null,"abstract":"<div><div>We present the updated recommendations of the Société française de radiothérapie oncologique (SFRO; the French society of radiation oncology) regarding the radiotherapy management of laryngeal cancers. Clinical examination in a seated position and nasofibroscopy are essential for accurately assessing laryngeal mobility, a crucial parameter in the therapeutic decision-making process for glottic cancer. In early-stage cancers, treatment selection depends on multiple factors and requires thorough consideration and multidisciplinary discussion. Between surgery and radiotherapy, the decision can be personalized to achieve an optimal balance between tumour control and the preservation of laryngeal function. In advanced-stage laryngeal tumours, the therapeutic approach is mainly based on two strategies: concomitant chemoradiotherapy or induction chemotherapy followed by chemoradiotherapy. However, in some cases where these approaches are not feasible, the treatment relies on upfront total laryngectomy, often followed by adjuvant therapy. With the exception of early-stage glottic tumours, where hypofractionation has proven its efficacy, there is no formal indication to modify the standard fractionation regimen. Due to the movements induced by respiration and swallowing, laryngeal mobility must be taken into account. Three-dimensional volumetric imaging is the gold standard for ensuring accurate daily patient positioning and monitoring weight loss. The follow-up of laryngeal cancers is crucial for the early detection of potential recurrences and for adjusting oncological management when necessary. It also plays a key role in patient rehabilitation, ensuring the best possible preservation of vocal and respiratory functions to optimize quality of life.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104727"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145045190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy of skin cancers","authors":"Emmanuelle Le Fur ,&nbsp;Matthieu Pallandre ,&nbsp;Adeline Pêtre ,&nbsp;Pierre Clavère ,&nbsp;Laurent Quéro ,&nbsp;Emmanuel Rio ,&nbsp;Véronique Bodez ,&nbsp;Christophe Hennequin","doi":"10.1016/j.canrad.2025.104724","DOIUrl":"10.1016/j.canrad.2025.104724","url":null,"abstract":"<div><div>Many histological types of skin cancers may be treated with radiation. In most cases, there are no randomised trials enabling to well define the place of radiotherapy nor the best dose-fractionation schedules. Radiation indications are based at best on large retrospective series and sometimes only on expert opinions. After reviewing the different irradiation techniques available, we will discuss the indications and techniques for irradiation for each skin disease. We will only discuss localised tumours. Considering their wide histological heterogeneity and clinical presentation, a discussion with a multidisciplinary team is absolutely necessary for difficult cases, with at least photographs of the lesion, or even with the presence of the patient who can be examined by the different players in the multidisciplinary team.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104724"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145045188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy of salivary gland tumours: 2025 update","authors":"Audrey Larnaudie ,&nbsp;Valérie Costes-Martineau ,&nbsp;Nolwenn Delaby ,&nbsp;Mélanie Doré ,&nbsp;Yoann Pointreau ,&nbsp;Sébastien Vergez ,&nbsp;Juliette Thariat","doi":"10.1016/j.canrad.2025.104772","DOIUrl":"10.1016/j.canrad.2025.104772","url":null,"abstract":"<div><div>Salivary gland tumours are relatively common among rare tumors and encompass both benign (mostly) and malignant entities (not to be initially misdiagnosed). Early diagnosis and appropriate management are crucial determinants of prognosis. The treatment of malignant tumours is guided by their wide histological diversity and grading, each requiring specific therapeutic strategies. Surgical resection remains the standard of care, with ipsilateral neck dissection recommended for intermediate- or high-grade malignancies. Postoperative radiotherapy is indicated for high-grade tumours, pT3 or higher stages, positive surgical margins, or lymph node involvement. In cases with extensive perineural invasion, particularly in adenoid cystic carcinoma, inclusion of the affected nerve pathways in the radiation field should be considered. Benign salivary gland tumours generally do not require radiotherapy, though its use may be discussed in selected cases of multirecurrent pleomorphic adenoma, where management remains controversial. This article summarizes and updates the recommendations of the Société française de radiothérapie oncologique (the French society for radiation oncology) regarding the indications and technical aspects of radiotherapy for salivary gland tumours, with emphasis on fractionation schedules, target volume delineation, and organ-at-risk sparing.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104772"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Respiratory motion management for external radiotherapy: 2025 update","authors":"Luc Simon ,&nbsp;Benoît Allignet ,&nbsp;Thomas Leroy ,&nbsp;Myriam Ayadi ,&nbsp;Julien Darréon","doi":"10.1016/j.canrad.2025.104763","DOIUrl":"10.1016/j.canrad.2025.104763","url":null,"abstract":"<div><div>Respiratory motion significantly impacts the precision of radiotherapy for thoracic and abdominal tumours. This article updates a prior review on respiratory management in radiotherapy, focusing on emerging technologies and clinical implementations. Respiratory-induced tumour motion, ranging from 1 to 3<!--> <!-->cm during free breathing, introduces uncertainties in imaging, target delineation, and dose delivery. To mitigate these, various respiratory motion management strategies have been developed, encompassing techniques such as deep inspiration breath-hold, internal target volume (ITV), mid-position approaches, gating, and real-time tracking. Recent advancements, including intelligent four-dimensional computed tomography, magnetic resonance imaging-guided linear accelerators, and surface-guided radiotherapy, enhance imaging quality and treatment precision. Dosimetric studies show these technologies reduce radiation exposure to healthy tissues, particularly in complex scenarios like left-sided breast cancer or locally advanced non-small cell lung cancer. Despite clear dosimetric benefits, clinical outcome comparisons among respiratory motion management techniques remain limited, necessitating further investigation. Successful respiratory motion management integration into clinical workflows requires interdisciplinary collaboration, patient-specific strategy selection, and systematic quality assurance. Emerging methods, such as mechanically assisted non-invasive ventilation and advanced magnetic resonance imaging-based gating, further refine motion management. Quality assurance protocols, including end-to-end tests using dynamic phantoms, ensure the reproducibility and accuracy of respiratory motion management strategies. This review highlights the importance of adapting respiratory motion management techniques to patient-specific needs and evolving technologies. By addressing respiratory motion, radiotherapy can achieve improved tumour targeting and reduced toxicity, paving the way for more effective and patient-centred cancer treatments.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104763"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy for brain metastases: 2025 update","authors":"Delphine Antoni ,&nbsp;Emmanuel Mesny ,&nbsp;Osman El Kabbaj ,&nbsp;Stéphanie Josset ,&nbsp;Kévin Quintin ,&nbsp;Adrien Boue-Rafle ,&nbsp;Agnès Tallet-Richard ,&nbsp;Igor Latorzeff","doi":"10.1016/j.canrad.2025.104765","DOIUrl":"10.1016/j.canrad.2025.104765","url":null,"abstract":"<div><div>We present the updated recommendations of the Société française de radiothérapie oncologique (the French Society for Radiation Oncology) on the indications and technical modalities of radiotherapy for brain metastases. The management of brain metastases represents a complex therapeutic challenge, due to the increase in patient life expectancy, technological advances in imaging and radiotherapy, specific and relevant prognostic classifications, the increased intracranial efficacy of certain systemic therapies and also the possible iterative irradiation sequences. The prevention of acute and late side effects is essential. Therapeutic strategies defined in a multidisciplinary manner are becoming increasingly personalized and must be rediscussed according to the evolution of the intracranial and extracranial disease.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104765"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy for cancers of the oesophagus, gastroesophageal junction, and stomach","authors":"Corentin Pasquier ,&nbsp;Gilles Créhange ,&nbsp;Véronique Vendrely ,&nbsp;Igor Bessières ,&nbsp;Laurent Quéro ,&nbsp;Florence Huguet ,&nbsp;Anouchka Modesto","doi":"10.1016/j.canrad.2025.104759","DOIUrl":"10.1016/j.canrad.2025.104759","url":null,"abstract":"<div><div>Oesophageal and gastric cancers are associated with a poor prognosis, as diagnosis is often delayed in fragile, comorbid patients. Radiotherapy plays a pivotal role in the treatment of oesophageal cancer. It is indicated in combination with chemotherapy for squamous cell carcinoma and for locally advanced, inoperable adenocarcinoma (i.e., non-operable patients or unresectable tumours). Additionally, chemoradiotherapy may be proposed in the preoperative setting for squamous cell carcinoma or for adenocarcinomas when peri-operative chemotherapy is not feasible. For resectable gastric adenocarcinomas, the indications for radiotherapy are limited. However, radiotherapy may be useful in a palliative setting in case of dysphagia or bleeding. Recent technological advances, such as image-guided radiotherapy and conformal intensity-modulated radiotherapy, have considerably improved the tolerance of treatments, particularly in curative approaches. These innovations optimize target volume coverage while limiting toxicity on adjacent organs at risk, notably the heart and lungs. We present here the updated guidelines of the Société française de radiothérapie oncologique (SFRO) regarding the indications and technical modalities of radiotherapy for oesophageal and gastric cancers.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104759"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy and brachytherapy for cervical cancer: Recommendations of the Société française de radiothérapie oncologique","authors":"Cyrus Chargari ,&nbsp;Anne Ducassou ,&nbsp;Adrien Laville ,&nbsp;François Lucia ,&nbsp;Adeline Petit ,&nbsp;Isabelle Flandin ,&nbsp;Abel Cordoba ,&nbsp;Sophie Renard ,&nbsp;Sylvain Demontoy ,&nbsp;Jean-Michel Hannoun-Lévi ,&nbsp;Carole Lafond ,&nbsp;Alexandre Escande","doi":"10.1016/j.canrad.2025.104753","DOIUrl":"10.1016/j.canrad.2025.104753","url":null,"abstract":"<div><div>External beam radiotherapy and brachytherapy are major treatments in the management of cervical cancer. For early-stage tumours with local risk factors, brachytherapy is a preoperative option. Postoperative radiotherapy is indicated according to histopathological criteria. For locally advanced tumours, chemoradiation is the standard treatment, followed by brachytherapy boost which is not optional. We present the 2025 update of the recommendations of the Société française de radiothérapie oncologique (the French society of radiation oncology) on the indications and techniques for external beam radiotherapy and brachytherapy for cervical cancer.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104753"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145294530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guide for paediatric radiotherapy procedures: 2025 update","authors":"Line Claude ,&nbsp;Jordan Bouter ,&nbsp;Farid Goudjil ,&nbsp;Emmanuel Jouglar ,&nbsp;Valentine Martin ,&nbsp;Luc Ollivier ,&nbsp;Marie Cantaloube ,&nbsp;Laetitia Padovani ,&nbsp;Anne Laprie ,&nbsp;Groupe français de radiothérapie pédiatrique (the French group of paediatric radiotherapy)","doi":"10.1016/j.canrad.2025.104756","DOIUrl":"10.1016/j.canrad.2025.104756","url":null,"abstract":"<div><div>A third of children with cancer receive radiotherapy as part of their initial treatment, which represents 800 paediatric irradiations per year in France, carried out in 15 specialized centres approved on the recommendations of the Institut national du cancer (the French national cancer institute). The treatment guidelines follow the recommendations of the Société francaise de lutte contre les cancers et les leucémies de l’enfant et de l’adolescent (SFCE; the French society for childhood cancers) or the French and European prospective protocols. The therapeutic indications, the technical and ballistic choices for complex cases are frequently discussed during bimonthly paediatric radiotherapy technical webconferences. With an overall survival being 80 % for all cancers combined, long-term toxicity logically becomes a major concern, making the treatments preparation complex. Irradiation methods include all the techniques currently available: intensity-modulated radiotherapy, stereotactic irradiation delivered in either standard or hypofractionated protocols, brachytherapy and proton therapy. We present the update of the recommendations of the Société française de radiothérapie oncologique (the French society for radiation oncology) on the indications, the technical methods of realization and the organisation and the specificities of paediatric radiation oncology.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104756"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145304970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy of pancreatic cancers: 2025 update","authors":"Maxime Bertrand-Chevrier ,&nbsp;Olivier Riou ,&nbsp;Alexandre Orthuon ,&nbsp;Igor Bessières ,&nbsp;Nicolas Jaksic ,&nbsp;Valentine Guimas ,&nbsp;Véronique Vendrely ,&nbsp;Florence Huguet","doi":"10.1016/j.canrad.2025.104716","DOIUrl":"10.1016/j.canrad.2025.104716","url":null,"abstract":"<div><div>We present the updated recommendations of the French Society of Radiotherapy Oncology (Société française de radiothérapie oncologique, SFRO) on radiotherapy for pancreatic cancer. The place of radiation therapy in the treatment of patients with resectable or locally advanced pancreatic cancer is still controversial. In the postoperative setting, the standard treatment is adjuvant chemotherapy with 5-fluorouracil, irinotecan and oxaliplatin (“folfirinox” regimen) for 6 months. Adjuvant chemoradiotherapy may be beneficial for patients with N0 cancer. After induction chemotherapy, neoadjuvant chemoradiotherapy is used for borderline tumours in order to increase the chances of complete resection (R0) even if its benefit on patient survival has not been demonstrated. For locally advanced tumours, induction chemotherapy followed in non-progressive patients by chemoradiotherapy increases local control and the chances of resectability. Intensity-modulated radiotherapy reduces the doses received by organs at risk. Tumour movements related to breathing must be taken into account. Stereotaxic radiotherapy increases the dose received by the tumour while protecting neighbouring healthy organs.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104716"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144880050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}